$0.39
4.88% day before yesterday
NYSE, Dec 27, 10:19 pm CET
ISIN
US80880W1062
Symbol
SCLX
Sector
Industry

Scilex Stock price

$0.39
-0.22 36.58% 1M
-1.40 78.21% 6M
-1.65 80.88% YTD
-1.30 76.92% 1Y
-9.65 96.12% 3Y
-9.46 96.04% 5Y
-9.46 96.04% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.02 4.88%
ISIN
US80880W1062
Symbol
SCLX
Sector
Industry

Key metrics

Market capitalization $93.27m
Enterprise Value $193.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 15.86
EV/Sales (TTM) EV/Sales 3.80
P/S ratio (TTM) P/S ratio 1.83
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 119.45%
Revenue (TTM) Revenue $50.83m
EBIT (operating result TTM) EBIT $-99.14m
Free Cash Flow (TTM) Free Cash Flow $12.19m
Cash position $6.89m
EPS (TTM) EPS $-1.02
P/E forward negative
P/S forward 1.40
EV/Sales forward 2.90
Short interest 8.34%
Show more

Is Scilex a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Scilex Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Scilex forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Scilex forecast:

Buy
100%

Financial data from Scilex

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
51 51
119% 119%
100%
- Direct Costs 20 20
106% 106%
40%
31 31
97% 97%
60%
- Selling and Administrative Expenses 114 114
9% 9%
223%
- Research and Development Expense 12 12
-
23%
-95 -95
-
-187%
- Depreciation and Amortization 4.28 4.28
-
8%
EBIT (Operating Income) EBIT -99 -99
11% 11%
-195%
Net Profit -119 -119
46% 46%
-234%

In millions USD.

Don't miss a Thing! We will send you all news about Scilex directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Scilex Stock News

Neutral
GlobeNewsWire
16 days ago
PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing the treatment for neurodegenerative and cardiometabolic disease, and non-opioid pain management products for the treatment of acute and chronic pain, today announced the closing of its...
Neutral
GlobeNewsWire
17 days ago
PALO ALTO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing the treatment for neurodegenerative and cardiometabolic disease, and non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has entere...
Neutral
GlobeNewsWire
17 days ago
PALO ALTO, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Scilex Bio, a controlling interest of joint venture by Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”) with IPMC Company, a representative company of the Bio Innovation Consortium (“IPMC”) which holds the exclusive rights to NeuroBiogen Company's (“NB”) KDS2010 global license, announced that KDS2010 (Tisolagiline) is a new revers...
More Scilex News

Company Profile

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Head office United States
CEO Jaisim Shah
Employees 105
Founded 2020
Website www.scilexholding.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today